Evidence Hub

High Eradication Rate of a Potassium-Competitive Acid Blocker-Based Minocycline, Furazolidone, and Bismuth Regimen for Refractory Helicobacter pylori Infection: A Real-World Study

Li JY, Han YY, Li DY, Liu JM, Zhou ZZ, Zhou YN, Tuo L, Yao XJ et al.

Helicobacter, 2026

368 participants

Abstract

Background: Management of refractory Helicobacter pylori (H. pylori) infection remains challenging due to increasing antibiotic resistance and limited effective rescue options. Minocycline and furazolidone retain low resistance rates, while potassium-competitive acid blockers (P-CABs) provide potent and sustained acid suppression. This study aimed to evaluate the efficacy and safety of a 14-day P-CAB-based regimen combining minocycline, furazolidone, and bismuth in patients with refractory H. pylori infection.

Methods: From January 2023 to October 2025, clinical data were collected from patients with refractory H. pylori infection who received the above regimen at Tongji Hospital, Wuhan, China. Eradication was assessed by a urea breath test performed at least 4 weeks after treatment. Adverse events during treatment were recorded.

Results: A total of 368 patients were included in modified intention-to-treat analysis. Of them, 183 (49.7%) had two previous eradication failures, 165 (44.8%) had three to four failures, and 20 (5.4%) had five or more failures. Among the 143 patients who underwent antibiotic resistance gene testing, the resistance rates to clarithromycin and quinolones were 96.5% and 79.7%, respectively. The H. pylori eradication rate was 92.7% (95% CI 89.5%-94.9%) in modified intention-to-treat analysis and 96.4% (95% CI 93.8%-97.9%) in per-protocol analysis. Adverse events occurred in 25.8% of patients and were predominantly mild to moderate, with dizziness…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free